The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

THE Philippine Health Insurance Corp. (PhilHealth) said on Wednesday that member contribution rates will not rise because they are fixed by law, adding that it will seek to offset the loss of ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

Non-steroidal anti-inflammatory drugs, or NSAIDs, are a class of drug that is commonly used (worldwide) to reduce ...

New data shows no increased cardiovascular risk of the osteoporosis drug vs anabolic agents — and even suggests a lower risk.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

MURRAY – Murray-Calloway County Hospital (MCCH) recently recognizes its Cardiac Catheterization Team for achieving the highest monthly procedure volume in the lab’s history this June.